Arcus Biosciences (RCUS) Assets Average (2018 - 2026)
Arcus Biosciences (RCUS) posted quarterly Assets Average of $1.1 billion for Q1 2026, down 9.11% year-over-year from $1.2 billion in Q1 2025, and up 1.09% quarter-over-quarter from $1.1 billion in Q4 2025.
Arcus Biosciences (RCUS) Assets Average (2018 - 2026) Analysis & Trends
Arcus Biosciences' Assets Average history runs 9 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Assets Average fell 9.11% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 9.11% YoY), while the FY2025 annual figure was $1.1 billion, up 1.96% from the prior year.
- Assets Average for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Assets Average was $1.6 billion in Q1 2022, with the low at $1.0 billion in Q3 2025.
- The 5-year median for Assets Average is $1.2 billion (2024), against an average of $1.2 billion.
- The sharpest annual moves came in 2022 and 2023: Assets Average surged 83.64% in 2022, then declined 18.54% in 2023.
- Arcus Biosciences' Assets Average stood at $1.3 billion in 2022, then slipped by 15.14% to $1.1 billion in 2023, then increased by 7.17% to $1.2 billion in 2024, then declined by 13.76% to $1.1 billion in 2025, then gained by 1.09% to $1.1 billion in 2026.
- Business Quant data shows RCUS's Assets Average at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 960.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 960.50 Mn |
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 1.02 Bn |
| Jun 30, 2025 | 1.14 Bn |
| Mar 31, 2025 | 1.18 Bn |
| Dec 31, 2024 | 1.23 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 1.14 Bn |
| Sep 30, 2023 | 1.21 Bn |
| Jun 30, 2023 | 1.24 Bn |
| Mar 31, 2023 | 1.28 Bn |
| Dec 31, 2022 | 1.35 Bn |
| Sep 30, 2022 | 1.44 Bn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.22 Bn |
| Sep 30, 2021 | 869.03 Mn |